BPC-157 After the July 2026 FDA PCAC Vote: Compounding Rules & Access

What the vote does not accomplish:

• Does not legalize or authorize BPC-157 compounding under current law
• Does not bind the FDA to accept the recommendation
• Does not permit compounding pharmacies to begin preparing BPC-157 immediately
• Does not establish interim enforcement discretion or Category 1 status automatically

As mintz.com explains, "nothing has legally changed yet. As we discussed in May 2026, an advisory committee vote is not an agency action, and FDA officials will have to make an ultimate decision on whether to accept or reject those recommendations."

Why FDA Staff Disagreed With PCAC

A critical aspect of the July 2026 vote is that FDA staff had recommended against BPC-157 inclusion before the PCAC meeting. According to sheppard.com, FDA scientific staff laid out a detailed case for caution and ultimately recommended against inclusion of all seven peptides. Staff raised concerns regarding:

• Physical and chemical characterization of BPC-157, noting that FDA described these as substances referenced in scientific literature with a variable number of amino acids and no settled chemical form
• Available safety information, including theoretical potential to promote cancer growth or trigger severe immune responses
• Evidence regarding effectiveness
• Other factors pertinent to compounding eligibility

After considering the FDA presentation, available scientific information, and public testimony, however, PCAC voted in favor of inclusion. The FDA must now reconcile this divergence between staff recommendation and committee recommendation—a process that may involve requesting additional information, developing regulatory safeguards, or taking additional time before proceeding.

The FDA's Next Steps: Proposed Rule to Final Rule

If the FDA decides to move forward, the formal pathway typically follows this sequence:

1. FDA Internal Decision

The agency must first determine whether to accept the PCAC recommendation, decline it, or request additional information. There is no statutory deadline for this decision.

2. Proposed Rule

If FDA decides to include BPC-157, the agency would publish a proposed rule in the Federal Register. This step opens a public comment period, allowing researchers, clinicians, compounding professionals, and other stakeholders to submit scientific data, clinical evidence, and other information supporting or opposing inclusion.

3. Administrative Record Review

FDA reviews all comments and evidence submitted during the comment period, evaluating their relevance to the agency's regulatory determination.

4. Final Rule

The FDA issues a final rule, which either adds BPC-157 to the 503A Bulks List or declines to do so. Only upon publication of a final rule does the substance become eligible for 503A compounding.

Historical Timeline: How Long Could This Take?

There is no fixed statutory deadline governing the rulemaking process. According to sheppard.com, the Agency's next step is formal notice-and-comment rulemaking to either include or exclude the six recommended peptides on the 503A bulks list—a process that could extend well into 2027 or 2028.

Historical precedent provides additional insight. The FDA published a proposed rule addressing bulk drug substances but did not issue the final rule until more than two years later, at which point the agency placed some substances on the 503A Bulks List and determined that others should not be included.

This history does not guarantee a similar timeline for BPC-157. FDA can prioritize issues receiving substantial regulatory attention, and peptide compounding has generated significant interest among compounders, physicians, researchers, and policymakers. Nevertheless, researchers should not assume that a favorable PCAC recommendation will result in a final rule within months.

Interim Enforcement Policy and Category 1 Status

Historically, FDA categorized nominated substances into three categories while evaluating them. Category 1 generally consisted of substances nominated with sufficient supporting information that did not appear to present significant safety risks. Under the interim enforcement policy, FDA generally did not intend to take enforcement action against compounders solely because a Category 1 substance had not yet been formally added to the 503A Bulks List, provided other enforcement policy conditions were met.

This framework was significant because FDA's evaluation process can take years. Category 1 effectively provided a regulatory bridge for certain substances during the review period.

However, according to afslaw.com, the real action will unfold in the months ahead as the FDA decides whether to place the six favorably-voted substances into interim Category 1 with accompanying enforcement discretion, or to proceed directly to formal rulemaking without any interim relief.

A favorable PCAC vote does not automatically confer Category 1 status. Researchers and compounding professionals should monitor whether the FDA reconsiders or modifies its interim regulatory posture for BPC-157 while the agency determines whether to proceed with rulemaking.

Current Legal Status: What Researchers and Clinicians Should Know

As of August 2026, BPC-157 remains an unapproved bulk drug substance not formally eligible for 503A compounding under current FDA regulations. According to hklaw.com, the PCAC's recommendations are nonbinding, and they did not result in any change in law. Thus, as of this writing, these peptides still cannot be lawfully compounded, and FDA can continue to take enforcement action against compounding pharmacies that make these peptides.

The PCAC recommendation does not change this legal status. Researchers investigating BPC-157's mechanisms and potential applications should continue to consult peer-reviewed literature and institutional review boards regarding appropriate research protocols.

What Researchers Should Monitor

1. Federal Register for proposed rule publication – This will signal that FDA has decided to move forward with rulemaking and will establish the public comment period.

2. FDA enforcement guidance updates – Changes to interim enforcement policy could affect practical access before final rulemaking is complete.

3. Peer-reviewed research on BPC-157 safety and efficacy – According to mintz.com, there is no robust clinical evidence of BPC-157's safety or efficacy for any of its popular uses. Additional clinical evidence could strengthen the regulatory case for inclusion.

4. FDA rulemaking activity – According to sheppard.com, the PCAC is also expected to convene again in February 2027 to consider additional peptide compounds, suggesting that the July meeting is the beginning of a larger regulatory conversation.

Conclusion

The July 2026 PCAC vote on BPC-157 represents an important regulatory development but not a final determination. The vote advances BPC-157 through the advisory phase of FDA's evaluation process, but FDA must still complete formal rulemaking before the peptide becomes eligible for 503A compounding. Researchers, clinicians, and compounding professionals should understand that the current legal status remains unchanged and that access through licensed compounding pharmacies depends on FDA's ultimate regulatory decision and the completion of notice-and-comment rulemaking. Monitoring Federal Register publications, FDA enforcement guidance, and peer-reviewed research will help stakeholders anticipate future developments in this evolving regulatory landscape.